Holy Stone Healthcare (HSHC) has once again won the Innovation award at the 2025 Taipei Biotech Awards. After years of dedicated research and development, HSHC has advanced its targeted, controlled biopolymer drug delivery system into the HylX drug delivery platform, designed to deliver therapeutics across key biological barriers to the brain, eye, and tumors.
Boston, USA-June 16. 2025–HSHC is participating in the BIO International Convention (USBIO 2025) held in Boston from June 16 to June 19, presenting our HylX drug delivery platform and assets. During the event, we engage in partnership discussions with global pharmaceutical companies
Kobe, Japan-May 14. 2025 -Holy Stone Health Care (HSHC) presented its proprietary HylX drug delivery technology platform at the 12th international Symposium of Drug Delivery System (SDDS 2025).
Dr. Eskouhie Tchaparian presented data on CA102N, the company’s novel pancreatic cancer drug candidate at the 2024 AACR annual meeting. The poster detailed a series of preclinical studies of CA102N activity in pancreatic cancer models. Pancreatic cancer is recognized as a highly aggressive and deadly form of cancer. The five-year survival rate for pancreatic cancer is only 13%; therefore, there is an urgent need for new therapeutic drugs to treat pancreatic cancer and improve the overall survival rate of patients. CA102N primarily inhibits pancreatic cancer cell growth by suppressing the PI3K/Akt/mTOR and Raf/MEK/ERK pathways, inducing apoptosis and inhibiting angiogenesis and cell migration. In in vivo pancreatic cancer models, CA102N demonstrated significant tumor growth inhibition and reduced liver metastasis. Observations of tumor samples from in vivo studies showed that CA102N alters pancreatic cancer stroma by changing its structure and enhances its permeability through the stromal barrier. Compared to current therapeutic drugs, CA102N is expected to overcome treatment limitations imposed by pancreatic tumor stroma. These results provide scientific evidence of CA102N's efficacy in treating pancreatic cancer. The company plans to file for orphan drug approval by the FDA . For more information, please refer to the following link: https://aacrjournals.org/cancerres/article/84/6_Supplement/5742/740087/Abstract-5742-Therapeutic-efficacy-of-CA102N-in?searchresult=1
ND108E, the novel neurodegenerative disease drug developed by Holy Stone Healthcare Co., Ltd., has taken a significant step in the fight against Alzheimer's disease (AD). The potential of ND108E to restore cognitive function and memory in postmenopausal women was published in the October 25, 2023 edition of the "International Journal of Molecular Sciences".
Holy Stone Healthcare Co., Ltd. a new drug pharmaceutical company, participated in the 16th Clinical Trials on Alzheimer’s Disease (CTAD) conference held in Boston, USA, where the advancements of the self-developed Alzheimer’s Disease new drug ND108E was presented.
CA102N is an innovative investigational anticancer drug designed for the treatment of solid tumors, including colorectal cancer. CA102N is a carrier-mediated drug delivery product with hyaluronic acid (HA) conjugated to Nimesulide. The Hyaluronic Acid – Drug Conjugation (HADC) platform is specifically engineered to target the CD44 receptor overexpressed in solid tumors. HSHC has secured the patent protection of its HADC platform. CA102N is a unique drug that inhibits tumor progression by inducing apoptosis and cell cycle arrest, and inhibiting metastasis and angiogenesis via targeting various signaling pathways such as the AKT pathway (PI3K/AKT/mTOR) pathway and promoting immune response. In addition, due to its direct tumor-targeting property via HA/CD44, an increase in drug accumulation at the target tumor site is observed, in vitro. CA102N, as monotherapy or in combination with LONSURF, was shown to be safe and well-tolerated in subjects with locally advanced or metastatic solid tumors and/or colorectal cancer in a phase I study which implies that the treatment may have potential as part of a combination therapy approach to target cancer more effectively. Further preliminary evidence of anti-tumor activity was also observed in solid tumors, a positive indication that the CA102N treatment might have therapeutic benefits in treating cancer. Exploratory analysis in the dose expansion cohort revealed a favorable median progression-free survival. HSHC is responsible for the ongoing research, development, commercialization, and manufacturing of CA102N.
CA102N is an innovative investigational anticancer drug designed for the treatment of solid tumors, including colorectal cancer. CA102N is a carrier-mediated drug delivery product with hyaluronic acid (HA) conjugated to Nimuselide. The Hyaluronic Acid – Drug Conjugation (HADC) platform is specifically engineered to target the CD44 receptor overexpressed in solid tumors. HSHC has secured the patent protection of its HADC platform. HSHC(4194.TW) submitted an Investigational New Drug (IND) application to the US FDA for CA102N to initiate a phase II clinical trial in subjects with metastatic colorectal cancer (mCRC) who failed the standard treatment.
In order to clarify the professional division of labor between "research and development of new drugs" and "sales and marketing of pharmaceutical products," to focus on enhancing the competitiveness of their respective industries and to effectively expand their business territories, Holy Stone Healthcare (HSHC) will be split-off the relevant businesses of agency distribution in Taiwan and private brand medical materials in Europe in accordance with the provisions of the "Company Act" and the "Business Mergers and Acquisitions Act." The relevant businesses will be transferred to the newly established Holy Young BioMedical Co., Ltd. (HYBMC), with new shares issued by HYBMC to all shareholders of HSHC as consideration.
IBD98-M, an anti-inflammatory drug for the treatment of Inflammatory Bowel Disease (IBD), submitted an application for Phase II clinical trial to the NMPA on February 17, 2023, and received notification of approval to conduct the Phase II clinical trial on May 19, 2023.
Phase 1 study of CA120N for mCRC from Holy Stone Healthcare, is published on 《Investigational New Drugs》on 04, Nov 2022.For more information, please visit https://link.springer.com/article/10.1007/s10637-022-01308-5
February 08, 2022 - Holy Stone Healthcare Co., Ltd. (4194.TW) completed the clinical study report for the Phase 1 clinical study of CA102N which is a new anti-cancer drug for the treatment of colorectal cancer.